Interestingly, 8 out of the 9 patients with ≥15% decrease of PRO-C3 in the fibrosis improvement/regression group had baseline PRO-C3 levels greater than 16 ng/ml (Fig. 2b), which is the median baseline levels of PRO-C3 in this cohort. Here, C3 is linked to fibrosis.